Jagran Josh Logo

Ranbaxy launched arthritis drug Infimab BOW015

Dec 2, 2014 17:10 IST

India’s largest pharmaceutical company, Ranbaxy Laboratories Limited, on 1 December 2014 launched arthritis drug Infimab (BOW015).

Infimab is India’s first bio-similar of infliximab drug. The product was launched at the Indian Rheumatology Association Conference (IRACON) in Chandigarh.

The drug can be used for treating various conditions including rheumatoid arthritis. Infimab also has an excellent treatment potential to treat other crippling painful arthritis like ankylosing spondylitis and psoriatic arthritis.

Infimab is being introduced in the Indian market through a licensing partnership with EPIRUS Biopharmaceuticals, Inc. a US and Swiss-based Biopharmaceutical Company focused on the global development and commercialization of bio-similar monoclonal antibodies.

Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai.

Infimab marks Ranbaxy’s entry into mAb (Monoclonal Antibodies) biologics, and will help the company provide greater access to quality biologic medicines in management of conditions like rheumatoid arthritis.

Rheumatoid arthritis is one of the most common chronic inflammatory diseases that cause disability. The literature estimates a prevalence of 0.5 percent to 0.75 percent in India.

Is this article important for exams ? Yes18 People Agreed
Read more Current Affairs on: Ranbaxy , arthritis drug , Infimab BOW015

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

Newsletter Signup
Follow us on
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK